This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in adult patients with indolent systemic mastocytosis (ISM). The purpose of the study is to determine the efficacy and safety profile of PA101 delivered via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using standard treatments.
The symptom scores for determining eligibility will be established during the 2-week Run-in Period using eDiary and the eligible patients will be randomly allocated in a 2:1 ratio to one of two treatment cohorts at the baseline visit. In Cohort 1 (n=24), patients will receive inhaled 40 mg PA101 three times daily and inhaled placebo three times daily via eFlow for 6 weeks each in a double-blind, 2-period crossover fashion with a 4-week washout period between the treatment periods. In Cohort 2 (n=12), patients will receive inhaled 40 mg PA101 three times daily via eFlow and oral cromolyn sodium 200 mg four times daily for 6 weeks each in an open label, 2-period crossover fashion with a 4-week washout period between the treatment periods. Patients will be allowed to use the same daily doses of pre-randomization H1 and H2 antihistamines as well as the same daily doses of any other allowed medications during each treatment period. Visits during each treatment period will occur at the baseline Visit, and at the end of Weeks 1, 2, 4, and 6. Blood and urine samples will be collected to test for various biomarkers. In a subset of patients, additional clinical assessments of the skin will be performed and blood samples will be collected for pharmacokinetic assessments. Clinical safety assessments will be performed in all patients at the start and end of each treatment period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
41
Hopital Necker - Enfants Malades
Paris, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Klinikum Darmstadt
Darmstadt, Germany
University Medical Center Mainz
Mainz, Germany
Overall symptom score
Mastocytosis Activity of Symptoms (MAS Plus) questionnaire for daily symptom score using eDiary
Time frame: 6 weeks
Disease specific quality of life (QoL)
Mastocytosis Impact Questionnaire (MIQ) for quality of life
Time frame: 6 weeks
Patient Global Impression of Change (PGIC) scale
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Technical University München
Munich, Germany
University of Salerno
Salerno, Italy
University Medical Center of Groningen
Groningen, Netherlands
Hospital Universitario de Fuenlabrada
Madrid, Spain